Recently, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Chongqing Sintaho Pharmaceutical Co., Ltd. ("Sintaho") have fully reached a strategic cooperation. Both parties will leverage Escugen's strengths in ADC new drug development, its ADC technology platform represented by EZWi-Fit®, and its Phase III ADC clinical pipeline, as well as Sintaho's advantages in the research and production of functional small molecule compounds, the production of high-activity antitumor APIs, cGMP management, and regulatory registration. Together, they will develop ADC products and services for both domestic and international markets and create a core competitive ADC innovative drug industry chain.
Wang Xiaodong, Chairman of Sintaho Pharmaceutical, said: "Escugen is a star enterprise in China's ADC field. As a strategic partner, since Sintaho established its ADC research platform in 2021, it has successfully developed several ADC toxins and linkers. The ADC compounds in cooperation with Escugen are distributed in its ADC clinical and commercial stages. The project time sensitivity, product cost, and quality of the ADC compounds have all been highly recognized by Escugen. Currently, the new ADC commercialization platform of Sintaho is about to be put into production, which can provide large-scale ADC compounds under GMP conditions and better meet the cooperation needs of partner companies."
Dr. Zhou Qing, Founder and CEO of Escugen, said: "Sintaho Pharmaceutical is one of the most representative enterprises in the field of small molecule antitumor APIs in China. It has been rated by Yaozh.com as the enterprise with the most varieties approved by the US FDA in Chongqing. After years of stable development, it has accumulated rich technical experience and professional talent reserves. We believe that under the strategic cooperation with Sintaho, Escugen will significantly strengthen its capabilities in translational research and cost control, further consolidate our technological innovation advantages in the EZWi-Fit® platform and the broader ADC field, and extend these achievements to a wider range of targets and clinical indications."
About Sintaho:
Sintaho has a complete EHS management system and a cGMP quality management system. Focusing on chemistry and technology, it specializes in three major business areas: high-activity/cytotoxic antitumor APIs, ADC small molecule compounds, and GLP-1 generic drugs. It can provide contract manufacturing services for related businesses and is a professional API service provider facing the global market.
About Escugen:
Established in 2017 in the Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, Escugen is an innovative biotechnology company with an international vision, committed to the development of ADC new drugs in the field of antitumor drugs. Escugen's lead clinical pipeline, ESG-401, is a differentiated TROP-2 ADC that has entered Phase III registration clinical studies. Escugen owns the next-generation ADC platform EZWi-Fit® with independent intellectual property rights. It uses efficient and low-toxicity camptothecin-based payloads and novel highly hydrophilic stable degradable linkers, surpassing international benchmark ADC technologies in multiple dimensions, including in vivo antitumor activity, resistance to multiple drug resistance, low clearance and high exposure pharmacokinetic characteristics, and safety. Escugen is leveraging this platform to expand the layout of its "First-in-Class" pipeline. Meanwhile, Escugen has non-exclusively licensed this platform technology to several companies to empower more ADC products.
